Agilent Technologies launches new AML cancer research panel

Agilent Technologies has announced the launch of ClearSeq AML, a next-generation sequencing (NGS) cancer research panel for use in the study of acute myeloid leukaemia (AML).

The first offering in the ClearSeq line of NGS cancer research panels targets 48 selected exons in 20 of the most commonly mutated genes found in AML, enabling a swift progression from sample processing to analysis in less than 48 hours.

ClearSeq AML provides 99.9 percent design coverage of targeted coding exons and was designed in collaboration with Dr Robert Ohgami and Dr Daniel Arber at Stanford University's department of pathology.

Jacob Thaysen, vice-president and general manager of Agilent's diagnostics and genomics group, said: "ClearSeq NGS panels are expert-identified products that will provide customers with a complete end-to-end anatomical-to-molecular genomics portfolio that includes solutions ranging from immunohistochemistry for cancer diagnosis to NGS for cancer research."

This comes shortly after the launch of the company's new 7200B Quadrupole Time of Flight Gas Chromatography Mass Spectrometer System, its most advanced version of this technology to date.